Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for Vaxcyte in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst C. Gould anticipates that the company will earn ($5.62) per share for the year. Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for Vaxcyte's current full-year earnings is ($4.21) per share.
Other analysts also recently issued research reports about the stock. The Goldman Sachs Group reduced their price target on shares of Vaxcyte from $138.00 to $100.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. Guggenheim reissued a "buy" rating and set a $160.00 price target on shares of Vaxcyte in a research report on Wednesday, March 12th. Bank of America decreased their price objective on Vaxcyte from $157.00 to $137.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Needham & Company LLC reissued a "buy" rating and issued a $90.00 price objective on shares of Vaxcyte in a research report on Tuesday, April 8th. Finally, Evercore ISI upgraded Vaxcyte to a "strong-buy" rating in a report on Monday, March 31st. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $136.50.
Read Our Latest Analysis on PCVX
Vaxcyte Stock Down 1.6%
NASDAQ PCVX traded down $0.56 during trading hours on Wednesday, hitting $34.88. 487,161 shares of the stock were exchanged, compared to its average volume of 1,435,504. Vaxcyte has a 12-month low of $27.66 and a 12-month high of $121.06. The stock has a 50-day moving average of $32.54 and a 200 day moving average of $64.03. The company has a market cap of $4.50 billion, a price-to-earnings ratio of -7.58 and a beta of 1.20.
Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same quarter in the prior year, the firm posted ($0.85) EPS.
Institutional Trading of Vaxcyte
A number of hedge funds and other institutional investors have recently modified their holdings of PCVX. Wells Fargo & Company MN increased its holdings in Vaxcyte by 53.7% during the 4th quarter. Wells Fargo & Company MN now owns 72,275 shares of the company's stock worth $5,916,000 after purchasing an additional 25,257 shares during the last quarter. TimesSquare Capital Management LLC increased its stake in shares of Vaxcyte by 53.7% in the fourth quarter. TimesSquare Capital Management LLC now owns 413,637 shares of the company's stock worth $33,860,000 after buying an additional 144,516 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its stake in Vaxcyte by 70.8% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 593,523 shares of the company's stock valued at $49,418,000 after acquiring an additional 246,049 shares during the last quarter. Smartleaf Asset Management LLC grew its stake in Vaxcyte by 188.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock worth $33,000 after purchasing an additional 260 shares in the last quarter. Finally, Rhumbline Advisers raised its stake in Vaxcyte by 5.5% during the first quarter. Rhumbline Advisers now owns 181,230 shares of the company's stock valued at $6,843,000 after buying an additional 9,416 shares in the last quarter. 96.78% of the stock is owned by hedge funds and other institutional investors.
About Vaxcyte
(
Get Free Report)
Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
See Also
Before you consider Vaxcyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxcyte wasn't on the list.
While Vaxcyte currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
